Nanjing Vazyme Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Nanjing Vazyme Biotech has a total shareholder equity of CN¥3.9B and total debt of CN¥500.9M, which brings its debt-to-equity ratio to 12.7%. Its total assets and total liabilities are CN¥4.9B and CN¥959.4M respectively.
Key information
12.7%
Debt to equity ratio
CN¥500.92m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥2.47b |
| Equity | CN¥3.94b |
| Total liabilities | CN¥959.43m |
| Total assets | CN¥4.90b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 688105's short term assets (CN¥3.4B) exceed its short term liabilities (CN¥731.2M).
Long Term Liabilities: 688105's short term assets (CN¥3.4B) exceed its long term liabilities (CN¥228.2M).
Debt to Equity History and Analysis
Debt Level: 688105 has more cash than its total debt.
Reducing Debt: 688105's debt to equity ratio has reduced from 18% to 12.7% over the past 5 years.
Debt Coverage: 688105's debt is not well covered by operating cash flow (14.3%).
Interest Coverage: Insufficient data to determine if 688105's interest payments on its debt are well covered by EBIT.